Company Encyclopedia
View More
name
AEON Biopharma, Inc.
AEON.US
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
1.898 T
AEON.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

    - FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data - - Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a ...

    GlobeNewswire·
    US
    AEON
    +11.37%
    GlobeNewswire·
    US
    AEON
    +11.37%

    AEON Biopharma, Inc. SEC 10-Q Report

    AEON Biopharma, Inc. released its Form 10-Q report for Q3 2025, highlighting a net loss of $4.5 million, an improvement from $6.2 million in Q3 2024. The company focuses on developing ABP-450 as a biosimilar to BOTOX®. AEON has shifted its strategy to a biosimilar regulatory pathway, discontinuing migraine trials. Operational challenges include dependency on Daewoong Pharmaceutical and the need for additional financing. The company expects continued losses and is seeking additional capital for its R&D and regulatory approval efforts.

    TradingView·
    US
    AEON
    +11.37%
    TradingView·
    US
    AEON
    +11.37%

    AEON Biopharma, Inc. | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    AEON
    +11.37%
    LB filings·
    US
    AEON
    +11.37%

    AEON Biopharma, Inc. | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    AEON
    +11.37%
    LB filings·
    US
    AEON
    +11.37%

    AEON Biopharma Slashes Debt by Over 90% with Strategic Transactions

    AEON Biopharma Inc. announced strategic transactions in November 2025, including a $6 million PIPE financing and a proposed note exchange with Daewoong Pharmaceutical, to reduce its debt by over 90%. These actions aim to strengthen its balance sheet, extend its cash runway into Q2 2026, and accelerate the ABP-450 biosimilar program development by up to six months.

    Reuters·
    US
    AEON
    +11.37%
    Reuters·
    US
    AEON
    +11.37%